- Home
- NBR vs JANX Comparison
NBR vs JANX Comparison
Compare NBR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | JANX |
|---|---|---|
| Founded | 1952 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.2M | 790.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBR | JANX |
|---|---|---|
| Price | $75.98 | $13.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $64.57 | $53.60 |
| AVG Volume (30 Days) | 386.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $2.27 | N/A |
| Revenue Next Year | $5.59 | $235.70 |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.27 | $12.12 |
| 52 Week High | $82.30 | $35.34 |
Technical Indicators
Market Signals| Indicator | NBR | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 45.22 |
| Support Level | $62.71 | $13.03 |
| Resistance Level | N/A | $13.79 |
| Average True Range (ATR) | 4.11 | 0.50 |
| MACD | -0.09 | 0.12 |
| Stochastic Oscillator | 68.12 | 51.59 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.